Abstract
Background
The clinical behaviour and oncologic outcome of diffuse sclerosing papillary thyroid carcinoma (DS-PTC) is poorly understood. The objectives of this study were to compare the clinicopathological characteristics and oncological outcomes of DS-PTC to classic PTC (cPTC) and tall cell PTC (TC-PTC).
Methods
After IRB approval, 86 DS-PTC, 2080 cPTC and 701 TC-PTC patients treated at MSKCC between 1986–2021 were identified. Clinicopathological characteristics were compared using Chi-Square. Kaplan-Meier and log rank were used to compare recurrence free survival (RFS), disease specific survival (DSS) and overall survival (OS). DS-PTC patients were propensity matched to cPTC and TC-PTC patients for further comparison.
Results
DS-PTC patients were younger with more advanced disease than cPTC and TC-PTC (p<0.05). Lymphovascular invasion (LVI), extranodal extension and positive margins were more common in DS-PTC (p<0.02). Propensity matching confirmed more aggressive histopathological features in DS-PTC. The median number of metastatic lymph nodes was significantly greater and DS-PTC metastases were RAI avid. DS-PTC 5-year RFS was 50.4%, compared to 92.4% in cPTC and 88.4% in TC-PTC (P<0.001). Multivariate analysis confirmed DS-PTC as an independent prognostic factor of recurrence. Ten-year DSS for DS-PTC was 100%, compared to 97.1% in cPTC and 91.1% in TC-PTC. Differentiated high-grade thyroid carcinoma DS had more advanced T-stage and worse 5-year RFS than DS-PTC.
Conclusion
DS-PTC presents with more advanced clinicopathological features than cPTC and TC-PTC. Large volume nodal metastases and LVI are characteristic features. Almost half of patients develop recurrence despite aggressive initial management. Despite this, with successful salvage surgery DSS is excellent.
Introduction
Papillary thyroid carcinoma (PTC) comprises 80% of thyroid cancers and typically has favourable recurrence and survival outcomes, with a 10-year disease specific survival (DSS) of 98%.1 Certain PTC subtypes which display more aggressive pathological and clinical behaviour are categorized as Intermediate Risk by the American Thyroid Association, including diffuse sclerosing, tall cell, columnar cell, solid, and hobnail subtypes.2 Diffuse sclerosing papillary thyroid carcinoma (DS-PTC) is a rare subtype of PTC, first described by Vickery et al in 1985.3 The reported incidence is 2 to 8% of PTC cases.4 DS-PTC is characterized by diffuse involvement of one lobe or the entire thyroid gland with extensive lymphatic permeation, fibrosis, numerous psammoma bodies, squamous metaplasia and associated chronic lymphocytic thyroiditis.5–6
DS-PTC occurs mostly in the second or third decades of life.4,7–10 It is considered to carry a greater risk of extrathyroidal extension (ETE), lymphovascular invasion (LVI), metastases and recurrence in comparison to classic PTC (cPTC).11 There is lack of definitive data in the literature regarding the prognostic significance of DS-PTC.6 The American Thyroid Association reports a 93% 10-year disease specific survival in DS-PTC,2 but it is unclear whether prognosis is equivalent or inferior to cPTC.12–14 There are no large, single-center studies which compares clinical and pathological data and oncological outcomes of DS-PTC to other PTC subtypes in the literature. Whether treatment regimens for surgery with or without adjuvant radioactive iodine should be modified in DS-PTC is unclear.
Tall cell (TC) PTC is the most common aggressive PTC subtype,15 with a poorer distant recurrence free survival and disease specific survival (DSS) than cPTC.16 Previous comparisons between TC-PTC and DS-PTC have not included histopathological features.17
The most current World Health Organisation (WHO) Classification of Thyroid Tumors (2022) defined differentiated high-grade thyroid carcinoma (DHGTC) as tumors with intermediate prognosis between well and undifferentiated (anaplastic) carcinomas.18 These tumors retain the cytoarchitectural features of well differentiated thyroid carcinoma but harbor high mitotic count and tumor necrosis. Due to its rarity, there has been no prior analysis comparing DHGTC, DS histotype (DHGTC-DS) to DS-PTC without tumor necrosis or marked mitotic count.
Incomplete knowledge of DS-PTC can lead to suboptimal management or inappropriate counselling of patients, so it is essential to accurately characterize this subtype. The objectives of this study were therefore to provide comprehensive clinical and histopathological characterization of DS-PTC in comparison to cPTC and TC-PTC using a large clinical and pathological dataset to better understand the patterns of presentation, treatment response and oncologic outcomes.
Materials and method
Patient selection
Institutional Review Board (IRB) approval and waiver of informed consent was obtained from Memorial Sloan Kettering Cancer Center (IRB Number: 16–160). The research was completed in accordance with the Declaration of Helsinki as revised in 2013. Retrospective review of a prospectively maintained database of 6260 patients undergoing surgery for thyroid malignancy between 1986 – 2015 at Memorial Sloan Kettering Cancer Center was carried out. For our comparison of PTC subtypes, a total of 2080 cPTC, 701 TC-PTC and 46 DS-PTC patients were identified from this database for inclusion. To increase the cohort we also identified DS-PTC patients who had surgery from 2015–2021 and those who had initial surgery at an outside institution from pathology department records. All patients including those that underwent surgery at an outside institution had detailed histopathology review performed at our institution by a head and neck pathologist. Following exclusion of patients with insufficient clinical data, a total of 86 DS-PTC patients were included in the study population.
Tumor definitions
Diffuse sclerosing PTC.
DS-PTC was confirmed by diffuse involvement of one or both lobes, marked tumor fibrosis, extensive lymphocytic infiltration, abundant psammoma bodies, squamous metaplasia and clusters of tumor cells in cleft-like spaces consistent with lymphatic vessels (Figure 1). A subset of DS-PTC cases were subclassified according to the WHO 2022 classification of endocrine tumors as DHGTC-DS if they harbored tumor necrosis and/or marked mitotic count (≥5 mitoses/2mm2 equivalent to 10 high-power fields, 400x) in most microscopes.18
Figure 1:
Photomicrographs of a diffuse sclerosing papillary thyroid carcinoma. A: Diffuse thyroid involvement by tumor (arrow) with chronic inflammation, fibrosis and abundant psammoma bodies (40X). B: Papillary tumor in a cleft like space (arrow) consistent with lymphatic (100X). C: Squamous metaplasia is typically seen (arrow) (400x). D: Nuclear features of papillary carcinoma in the form of clear, irregular, overlapping nuclei (arrow) (600x)
Classic PTC.
A tumor was classified as cPTC if it had >1% papillary formations and was composed of cells showing the characteristic nuclear features of papillary carcinoma (irregular enlarged clear nuclei with grooves and pseudo-inclusions). Tumors were required to contain <30% tall cells and lack tumor necrosis or marked mitotic count (≥5 mitoses/2mm2).
Tall cell PTC.
A tumor was classified as TC-PTC if it contained 30% or more tall cells without tumor necrosis or marked mitotic count (≥5 mitoses/2mm2). Tall cells were defined as cells with height at least twice their width and having an eosinophilic cytoplasm with a low nuclear-cytoplasmic ratio. Nuclear features were characteristic of PTC.
Data collection
Data was collected regarding patient clinical (sex, age), pathological (TNM stage, lymphatic and vascular invasion, ETE, surgical margin, multifocality, mitotic count, microscopic extranodal extension (ENE), tumor encapsulation, number of nodal metastases) and treatment (surgical procedure, adjuvant therapy, radioactive iodine) characteristics. TNM was defined according to the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of thyroid carcinomas.19
Statistical analysis
Oncological outcomes included OS, DSS and recurrence free survival (RFS). Local, regional, and distant structural recurrence events were recorded. The OS, DSS and RFS were calculated using the Kaplan-Meier method. Differences in survival were assessed using the log-rank test. Unadjusted and adjusted hazard ratios (HR) were calculated using the Cox proportional hazards regression model. Factors found to be significant in univariable analysis were included in multivariable analysis. The follow-up interval was calculated in months from the date of initial curative surgery to death or last known status. All statistical analyses were completed using R version 4.2.0 (R Core Team, 2022). To select which DS-PTC, cPTC and TC-PTC patients to include in propensity matching we selected age, sex, T, N and M stage as our propensity score matching criteria to control for possible confounders. R package “MatchIt” and “Nearest Neighbor Matching” were used at a 1:1 ratio.20 Greedy nearest neighbor matching was used, where each treated unit is sequentially matched with k-nearest control units (k=1) with the closest propensity score.
Results
Clinicopathologic features of DS-PTC compared to cPTC and TC-PTC.
Table 1 compares the clinicopathologic features of DS-PTC to cPTC and TC-PTC. Patients with DS-PTC were younger on average than both cPTC and TC-PTC (p < 0.001), with median age of 24, 44, and 50 years respectively. The histogram in Supplementary Figure S1 shows that DS-PTC predominantly presents under the age of 25 years. There was no difference in DS-PTC tumor and pathologic characteristics when comparing patients under the age of 55 (N = 78) with patients over the age of 55 (N = 8) (p > 0.05). There was no significant difference in recurrence free survival between the two age groups (p = 0.59).
TABLE 1.
PATIENT, HISTOPATHOLOGY AND TREATMENT CHARACTERISTICS FOR DIFFUSE SCLEROSING PTC, CLASSICAL PTC AND TALL CELL PTC
| Variable | Diffuse Sclerosing PTC (n=86)1 | 1%1 | Classical PTC (n=2,080)1 | 1%1 | p-value2 | Tall cell PTC (n=701)1 | 1% | p-value2 |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Age | 24 (18,37) | NA | 44 (24,55) | NA | <0.001 * | 50 (39,59) | NA | <0.001 * |
| Sex | 22 | 26% | 627 | 30% | ||||
| Male | 64 | 74% | 1453 | 70% | 0.4 | 200 | 29% | 0.6 |
| Female | 501 | 71% | ||||||
| pT Stage | 36 | 43% | 1,452 | 70% | <0.001 * | |||
| T1 | 27 | 32% | 395 | 19% | <0.001 * | 451 | 64% | |
| T2 | 18 | 21% | 151 | 7.30% | 87 | 12% | ||
| T3 | 3 | 3.60% | 81 | 3.90% | 80 | 11% | ||
| T4 | 83 | 12% | ||||||
| pN Stage | 4.70% | 1,166 | 56% | <0.001 * | ||||
| N0 | 4 | 19% | 507 | 24% | <0.001 * | 335 | 48% | |
| N1a | 16 | 77% | 406 | 20% | 229 | 33% | ||
| N1b | 66 | 137 | 20% | |||||
| M Stage | 81 | 94% | 2,055 | 99% | 0.047 * | |||
| M0 | 5 | 5.80% | 25 | 1.20% | 0.006 * | 687 | 98% | |
| M1 | 14 | 2.00% | ||||||
| Gross ETE | 52 | 90% | 1829 | 88% | 0.7 | 534 | 76% | 0.019 * |
| No | 6 | 10% | 251 | 12% | 167 | 24% | ||
| Yes | ||||||||
| Microscopic ETE | 25 | 29% | 1,307 | 63% | ||||
| No | 61 | 71% | 773 | 37% | 238 | 34% | 0.4 | |
| Yes | <0.001 * | 463 | 66% | |||||
| Margin | 60 | 70% | 1,813 | 88% | 0.017 * | |||
| Negative | 26 | 30% | 245 | 12% | <0.001 * | 563 | 81% | |
| Positive | 134 | 19% | ||||||
| Multifocality | 0 | 0% | 828 | 40% | <0.001 * | |||
| No | 86 | 100% | 1,240 | 60% | <0.001 * | 266 | 38% | |
| Yes | 430 | 62% | ||||||
| LVI | 0 | 0% | 1,722 | 84% | <0.001 * | |||
| No | 86 | 100% | 321 | 16% | <0.001 * | 576 | 83% | |
| Yes | 119 | 17% | ||||||
| ENE | 87% | |||||||
| No | 46 | 58% | 1,701 | 13% | 570 | 83% | <0.001 * | |
| Yes | 33 | 42% | 261 | <0.001 * | 106 | 17% | ||
| Encapsulation3 | 70 | 89% | 688 | 34% | ||||
| No | 9 | 11% | 1,320 | 66% | <0.001 * | 399 | 60% | <0.001 * |
| Yes | 269 | 40% | ||||||
| Surgery Performed | 80 | 93% | 1815 | 87% | 0.11 | 632 | 90% | 0.4 |
| Total Thyroidectomy | 6 | 7% | 265 | 13% | 69 | 10% | ||
| Less than total | ||||||||
| Neck Dissection | 13 | 15% | 1380 | 66% | <0.001 * | 468 | 67% | <0.001 * |
| Not performed | 73 | 85% | 700 | 34% | 233 | 33% | ||
| Performed | 19 | 22% | 294 | 14% | 91 | 13% | ||
| Central only | 4 | 5% | 109 | 5% | 31 | 4% | ||
| Lateral only | 50 | 58% | 297 | 14% | 111 | 16% | ||
| Central and lateral | ||||||||
| RAI treatment | 79 | 93% | 885 | 42% | <0.001 * | 382 | 55% | <0.001 * |
| Yes | 6 | 7% | 1195 | 58% | 319 | 45% | ||
| No | ||||||||
Median (IQR); n (%)
Kruskal-Wallis rank sum test; Pearson’s Chi-squared test
Encapsulation refers to the main tumor nodule.
Missing values excluded from count. Percents rounded.
Denotes significant p-values
LVI = lymphovascular invasion; ENE = extranodal extension; ETE = extrathyroidal extension
DS-PTC patients were more likely to present with T2 or T3 disease compared to cPTC and TC-PTC patients (p<0.001). Those with TC-PTC were more likely to present with T4 disease (3.6% DS-PTC; 3.9% cPTC; 12% TC-PTC). Gross ETE was also more common in TC-PTC than DS-PTC (24% vs 10%; p = 0.019). DS-PTC patients were more likely to have positive margins (30% DS-PTC, 12% cPTC, TC-PTC 19%; p<0.005). Multifocality was seen in 100% of DS-PTC since by definition they diffusely involve one or both thyroid lobes, significantly more than cPTC (60%) and TC-PTC (62%) (p<0.001). Significantly more tumor encapsulation was seen in cPTC and TC-PTC (11% DS-PTC, 66% cPTC, 40% TC-PTC; p < 0.001). Encapsulation in DS-PTC refers to the presence of capsule in the main tumor nodule.
N1b disease occurred in 77% of DS-PTC patients, compared to 20% in TC-PTC and cPTC (p<0.001). DS-PTC patients were more likely to have 20 or more cervical nodes positive for metastatic disease, in comparison to cPTC and TC-PTC (33.7% (29/86) DS-PTC, compared to 3.4% (70/2080) of cPTC and 3.7% (26/701) of TC-PTC patients). A finding of microscopic ENE was more likely in DS-PTC (42% DS-PTC; 13% cPTC; 17% TC-PTC; P<0.001) and 100% of DS-PTC tumors demonstrated lymphovascular invasion (LVI), in comparison to 15% of cPTC and 17% of TC-PTC (p < 0.001). 8.7% (6/69) of DS-PTC tumors had blood vessel invasion. There was no significant difference in regional or distant recurrence for DS-PTC with or without blood vessel invasion (p = 0.89 and 0.6). Distant metastases were present at diagnosis in 5.8% of DS-PTC, compared to 1.2% of cPTC and 2% of TC-PTC (p < 0.05). All metastases on presentation in DS-PTC patients were pulmonary. 80% (4/5) of these patients with pulmonary metastases were under the age of 18 (median age 17.07 years; range 6.88 – 29.52 years).
Treatment characteristics
Table 1 shows the treatment of DS-PTC, cPTC and TC-PTC. 93% of DS-PTC, 87% of cPTC and 90% of TC-PTC underwent total thyroidectomy (p>0.05). The percentage of patients undergoing therapeutic neck dissection was significantly higher in DS-PTC (85%) than TC-PTC (33%) and cPTC (34%) (p<0.001). Most neck dissections in DS-PTC involved both the central and lateral compartments. Post-operative radioactive iodine (RAI) was used more frequently in DS-PTC (93%) patients, compared to cPTC (42%) and TC-PTC (55%) (p<0.001).
Survival and recurrence outcomes
The median follow-up for DS-PTC was 53 months (range 1 – 247 months). The Kaplan-Meier plot in Figure 2A illustrates the significantly increased risk of recurrence in DS-PTC patients in comparison to cPTC and TC-PTC (p<0.0001). Patients with DS-PTC had a poorer 5-year recurrence free survival (RFS) compared to patients with cPTC and TC-PTC (50.4% 5-year RFS for DS-PTC; 92.4% cPTC; 88.4% TC-PTC). In DSPTC, the median time to locoregional recurrence was 36 months (IQR 46 months). 82% (27/33) of patients with regional recurrence had recurrence in a neck level that had been dissected at initial surgery. These patients had a median number of 22 metastatic lymph nodes and 62.9% had ENE. Univariable analysis showed ENE (HR 2.63, CI 1.24–5.57, p = 0.012) and number of positive lymph nodes as a continuous variable (HR 1.03, CI 1.01 – 1.05, p = 0.005) to be risk factors for locoregional recurrence in DSPTC patients (n = 86). Number of positive lymph nodes was an independent risk factor for locoregional recurrence after multivariable analysis (HR=1.03, 1.00–1.06, p = 0.041) (Supplementary Table S1). Despite the high rate of recurrence, 10-year disease specific survival (DSS) was 100% in DS-PTC, with no patients dying of disease. In comparison, 10-year DSS was 97.1% cPTC and 91.1% in TC-PTC. The Kaplan-Meier plot in Figure 2B demonstrates the significantly worse DSS in cPTC and TC-PTC, in comparison to DS-PTC (p = 0.015).
Figure 2:
Kaplan-Meier plot of Recurrence-Free Survival (A) and Disease-Specific Survival (B) stratified by histology
Recurrence occurred in 45.3% (39/86) of DS-PTC patients, with regional recurrence predominating. The distribution of recurrence is shown in Supplementary Figure S2, with 40.7% (35/86) developing locoregional recurrence and 7% (6/86) developing distant recurrence (five lung and one bone metastases). Five-year regional RFS for DS-PTC was 56% compared to 93.7% for cPTC and 90.3% for TC-PTC (p<0.0001) (Figure 3a). The 5-year local recurrence free survival for DS-PTC was poorer than cPTC and TC-PTC (89.5% DS-PTC; 98.9% cPTC; 98.3% TC-PTC) (Figure 3b). The overall local recurrence rate for DS-PTC was 10.4% (9/86); 1.1% for cPTC (24/2182); 1.7% for TC-PTC (12/701).
Figure 3:
Kaplan-Meier plot of 5-Year Regional Recurrence-Free Survival (A) and 5-Year Local Recurrence-Free Survival (B).
Survival outcomes after Propensity matching analysis
To adjust for the effect of advanced TNM stage in DS-PTC patients, we carried out propensity matching analyses. 84 DS-PTC patients were propensity matched to 84 cPTC and 84 TC-PTC patients on age, sex, T, N and M stage (Table 2). Supplementary figures S3 and S4 show reduced variability in standardized mean differences pre- and post-propensity matching. Supplementary figures S5 and S6 show successful propensity matching of selected variables of interest. DS-PTC continued to demonstrate a greater rate of microscopic ETE, LVI, multifocality and positive margins than cPTC (p≤0.006). DS-PTC had a significantly increased likelihood of LVI and multifocality (p < 0.001) than TC-PTC. There was no difference between the groups in gross ETE or microscopic ENE. The RFS was significantly worse for DS-PTC in comparison to cPTC and TC-PTC after propensity matching (p<0.0001) (Figures 4a and 4b). Propensity matching analysis using age, sex and T stage as the matching variables gave median number of metastatic lymph nodes as 11.5, 2 and 3 for DS-PTC, cPTC and TC-PTC respectively (p<0.05).
TABLE 2.
COMPARISON OF PATHOLOGY CHARACTERISTICS FOR CLASSICAL AND TALL CELL PTC PROPENSITY MATCHED TO DIFFUSE SCLEROSING PTC
| Variable | Classical PTC (n=84)1 | Diffuse Sclerosing PTC (n=84) | p-value2 | Tall Cell PTC (n=84)1 | Diffuse Sclerosing PTC (n=84) | p-value2 |
|---|---|---|---|---|---|---|
|
| ||||||
| Gross ETE | 78 (93%) | 50 (89%) | 0.5 | 72 (86%) | 50 (89%) | 0.5 |
| No | 6 (7.1%) | 6 (11%) | 12 (14%) | 6 (11%) | ||
| Yes | ||||||
| Microscopic Extension | 39 (46%) | 24 (29%) | 0.006 * | 23 (46%) | 24 (29%) | 0.9 |
| No | 45 (54%) | 60 (71%) | 61 (54%) | 60 (71%) | ||
| Yes | ||||||
| Margin | 66 (89%) | 59 (70%) | 0.003 * | 59 (70%) | 0.084 | |
| Negative | 8 (11%) | 25 (30%) | 67 (82%) | 25 (30%) | ||
| Positive | 15 (18%) | |||||
| Multifocality | 32 (38%) | 0 (0%) | <0.001 * | 0 (0%) | <0.001 * | |
| No | 52 (62%) | 84 (100%) | 31 (37%) | 84 (100%) | ||
| Yes | 53 (63%) | |||||
| LVI | 60 (72%) | 0 (0%) | <0.001 * | 69 (83%) | 0 (0%) | <0.001 * |
| No | 23 (28%) | 84 (100%) | 14 (17%) | 84 (100%) | ||
| Yes | ||||||
| Extra-nodal Extension | 44 (59%) | 45 (58%) | 0.9 | 53 (65%) | 45 (58%) | 0.4 |
| No | 30 (41%) | 32 (42%) | 29 (35%) | 32 (42%) | ||
| Yes | ||||||
| Encapsulation3 | 35 (43%) | 72 (89%) | <0.001 * | 48 (59%) | 72 (89%) | <0.001 * |
| No | 47 (57%) | 9 (11%) | 33 (41%) | 9 (11%) | ||
| Yes | ||||||
Percents may not add up to 100 due to rounding. Missing observations excluded from counts
Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test
Encapsulation refers to the main tumor nodule
LVI = lymphovascular invasion
Denotes significant p-values
Figure 4:
Recurrence free survival of propensity matched cPTC and DS-PTC cohorts (A) and propensity matched TC-PTC and DS-PTC cohorts (B)
Prognostic factors of recurrence free survival
Table 3 lists variables affecting RFS for the combined cohort of DS-PTC, cPTC and TSV-PTC. On univariate analysis, age (p<0.05), female sex, T-stage, cervical nodal metastases, gross ETE, microscopic ETE, positive margins, LVI and microscopic ENE conferred worse RFS (p<0.001). Patients with DS-PTC histology were over 7 times more likely to recur than cPTC (HR 7.57; p<0.001). Multivariate analysis confirmed a histological diagnosis of DS-PTC as an independent prognostic factor of recurrence (p<0.001).
TABLE 3.
UNIVARIABLE AND MULTIVARIABLE ANALYSIS OF RECURRENCE-FREE SURVIVAL FOR DIFFUSE SCLEROSING, CLASSICAL, AND TALL CELL PTC (N=2,867)
| Factor | Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR1 | 95% CI1 | p-value | HR1 | 95% CI1 | P-value | ||
|
| |||||||
| Age | (Cont) | 0.99 | 0.98, 1.00 | 0.023 * | 1 | 0.99, 1.01 | 0.5 |
| Sex | Male | REF | REF | ||||
| Female | 0.65 | 0.50, 0.83 | <0.001 * | 0.84 | 0.62, 1.14 | 0.3 | |
| T stage | T1/2 | REF | REF | ||||
| T3/4 | 2.95 | 2.27, 3.84 | <0.001 * | 1.38 | 0.84, 2.28 | 0.2 | |
| N stage | N0 | REF | REF | ||||
| N1a/N1b | 4.18 | 3.06, 5.69 | <0.001 * | 2.28 | 1.46, 3.56 | <0.001 * | |
| Histology | cPTC | REF | |||||
| DS-PTC | 7.57 | 5.29, 10.8 | <0.001 * | 2.39 | 1.26, 4.54 | 0.008 * | |
| TC-PTC | 1.33 | 0.99, 1.77 | 0.056 | 1.13 | 0.80, 1.58 | 0.5 | |
| Gross ETE | No | REF | |||||
| Yes | 2.6 | 1.98, 3.41 | <0.001 * | 1.26 | 0.76, 2.08 | 0.4 | |
| Microscopic ETE | No | REF | REF | ||||
| Yes | 3.02 | 2.29, 3.98 | <0.001 * | 1.16 | 0.78, 1.71 | 0.5 | |
| Margins | Negative | REF | REF | ||||
| Positive | 2.86 | 2.19, 3.73 | <0.001 * | 1.54 | 1.08, 2.19 | 0.017 * | |
| Multifocality | No | REF | |||||
| Yes | 1.8 | 1.36, 2.39 | <0.001 * | 1.03 | 0.73, 1.45 | 0.8 | |
| LVI | No | REF | REF | ||||
| Yes | 2.44 | 1.88, 3.16 | <0.001* | 0.96 | 0.66, 1.39 | 0.8 | |
| ENE | No | REF | REF | ||||
| Yes | 4.14 | 3.17, 5.39 | <0.001 * | 1.4 | 0.97, 2.03 | 0.073 | |
| Positive LN | (Cont) | 1.06 | 1.05, 1.06 | <0.001 * | 1.02 | 1.01, 1.04 | 0.006 * |
HR = Hazard Ratio, CI = Confidence Interval. Unknown observations excluded from analysis.
NA = not attempted multivariate analysis for variables not significant in univariate analysis.
ETE = extrathyroidal extension; LVI = lymphovascular invasion; ENE = extranodal extension
Denotes significant p-values
Prognostic factors of recurrence free survival in patients with DS-PTC alone
In DS-PTC alone, microscopic ENE was the only factor that conferred worse RFS (p<0.05). There were no independent prognostic factors of RFS on multivariate analysis.
Management of recurrence in DS-PTC
DSS was excellent in DS-PTC despite the high incidence of recurrence, meaning patients were successfully salvaged. 51.5% (17/33) of patients with regional recurrence had salvage neck dissection and 33.3% (11/33) with regional recurrence were able to be observed due to small volume disease. Five of 9 (55.5%) patients with local recurrence were also able to be observed. Multiple locoregional recurrences occurred in four patients (4/86, 4.7%). Three patients had at least two locoregional recurrences that were treated with neck dissection on each occasion. One patient had two separate locoregional recurrences which were observed.
Comparison between DS-PTC lacking high grade features and DHGTC-DS histotype
10.5% (9/86) of patients were sub-categorised as DHGTC-DS due to tumor necrosis or marked mitotic count (≥5 mitoses/2mm2). Supplementary Table S2 compares the clinicopathologic features of DS-PTC lacking high grade features to DHGTC-DS. DHGTC-DS presented with more advanced T-stage (p = 0.007), increased likelihood of gross ETE (p = 0.029) and increased mitotic count (p = 0.006). Median number of positive nodes was 35 in DHGTC-DS in comparison to 13 in DS-PTC (p = 0.051). 5-year RFS was 38.9% in DHGTC-DS and 51% in DS-PTC (p = 0.19).
Radioactive Iodine Avidity of DS-PTC
RAI avid lymph node metastases were identified on post-therapy radioactive iodine scan in 33% (24/72), while 80% (4/5) of patients with distant metastases demonstrated RAI avid disease. RAI uptake occurred in 44% (4/9) of DHGTC-DS patients with regional metastases and 100% (2/2) of DHGTC-DS patients with distant metastases.
Discussion
Robust data regarding DS-PTC is lacking due to the rarity of this histological subtype. Large population level analyses have been undertaken,10–11 while meta-analyses have shown heterogenicity in findings and opposing survival outcomes.4–5 There have been no previous studies which compare matched cohorts of DS-PTC, cPTC and TC-PTC with DS-PTC subjected to a meticulous histopathologic examination.
In our study, patients with DS-PTC presented at a median age of 24 years, which supports data demonstrating DS-PTC patients present in the third decade of life.4,9 Our data supports prior literature that shows DS-PTC typically presents with more advanced disease than cPTC.8,10–12,14,21 In addition, the number of metastatic nodes was significantly greater than in cPTC and TC-PTC. This pattern reflects the strong tendency for LVI in DS-PTC, predominantly to the lymphatic vessels.6 The LVI rate of 100% is more than double the rate cited in previous literature.11,22 Accompanied by a greater rate of N1b disease and ENE, this results in DS-PTC patients requiring more extensive surgery. Previous comparisons of DS-PTC and TC-PTC have not included histopathological features except in the pediatric population.23 Our study has shown DS-PTC to have a significantly greater rate of LVI, ENE and positive margins than in TSV-PTC. Significantly more tumor encapsulation was seen in cPTC and TC-PTC, a characteristic that infers more indolent behaviour.
A 5% rate of distant metastases at presentation is similar to that reported in the literature.9 However, the overall recurrence rate of 45.3% is significantly higher than previously cited.9,11 Most recurrence occurred in regional lymph nodes and 82% (27/33) of these occurred in a previously dissected neck level. These patients had a high nodal burden and 62.9% rate of ENE at initial surgery, suggesting that large number of positive lymph nodes and incidence of ENE are important factors in DSPTC recurrence. This was confirmed by univariable and multivariable analysis, which showed ENE and increasing number of positive nodes to be risk factors for locoregional recurrence in DS-PTC (Supplementary Table S1).
DS-PTC has not been shown to be an independent risk factor for recurrence until now. We have shown through multivariate analysis that a diagnosis of DS-PTC has a hazard ratio of 7.57 for recurrence (P<0.001). Close surveillance after initial treatment is therefore required to identify recurrence and implement salvage surgery if necessary.
Meta-analysis of 641 patients with DS-PTC inferred that DS-PTC prognosis is similar to cPTC when managed with aggressive treatment protocols.9 However, results are conflicting in other meta-analyses, SEER studies and single center studies.9–11,13,24–25 Excellent DSS in our study may be due to the tendency for DS-PTC to affect adolescents and young adults. However, young patients with DS-PTC (<55 year) had similar outcomes and histopathologic features to older counterparts in this study. Other factors such as the unique molecular profile of DS-PTC (which is different from cPTC) may therefore play a role. The molecular profile of DS-PTC is characterized by increased RET rearrangements but fewer BRAFV600E mutations, the latter being associated with poor outcome in PTC.18,26–28 NCOA4::RET fusions have been associated with advanced stage and persistent disease, CCDC6::RET fusions with disease remission.26–27 Further genetic studies are required to assess the effect of RET fusions on oncologic outcomes. In our study three patients had multiple recurrences despite adjuvant RAI and repeat salvage neck dissections. Such patients may benefit from the option of RET targeted treatments in the future.
There are no previous reports regarding RAI avidity of DS-PTC. Our study shows that regional and distant metastases in DS-PTC can concentrate RAI on post-surgical scans. Recurrence is typically treated with salvage surgery. However, management of recurrence has not been addressed in the literature. We have shown that active surveillance of small volume non-progressive disease is acceptable. Comparison between DHGTC-DS and DS-PTC is a novel analysis in this study. DHGTC-DS tumors had more advanced T-stage and incidence of gross ETE. However, the difference in 5-year RFS was not significant. Further studies are required to improve understanding of differences in genetics, histopathology and survival between the two groups.
Our study has several limitations that warrant consideration. This is a retrospective review and is therefore susceptible to the inherent biases associated with such data. The inclusion of patients that had initial treatment at outside institutions improves the statistical power of our study but adds potential variability in radiological work-up.
Conclusion
Our study illustrates the unique clinical and pathological characteristics of DS-PTC that distinguish it from cPTC and TC-PTC. The diagnosis of DS-PTC alone is an independent prognostic factor for recurrence, meaning accurate histological diagnosis is essential in the treatment and outcome of patients with aggressive cPTC subtypes. Large volume nodal metastases and LVI are characteristic features of DS-PTC and almost half of patients develop recurrence despite aggressive initial management. Nevertheless, DSS is favourable in comparison to cPTC and TC-PTC after successful salvage surgery.
Supplementary Material
Figure S1: Histogram showing distribution of age at surgery in DS-PTC compared to cPTC and TC-PTC
Figure S2: Distribution of recurrence in DS-PTC (N = 39)
Figure S3: Standardized mean difference plot before and after matching for DS-PTC and cPTC
Figure S4: Standardized mean difference plot before and after matching for DS-PTC and TC-PTC
Figure S5: Unadjusted (pre-match) and adjusted (post-match) propensity score distribution graphs A) Age B) Sex C) T Stage D) N Stage E) M Stage. Blue = cPTC; Green = DS-PTC
Figure S6: Unadjusted (pre-match) and adjusted (post-match) propensity score distribution graphs A) Age B) Sex C) T Stage D) N Stage E) M Stage. Red = TC-PTC; Green = DS-PTC
Synopsis.
Diffuse sclerosing papillary thyroid carcinoma characteristically presents with large volume nodal metastases and lymphatic invasion. Almost half of patients develop recurrence despite aggressive initial management. Despite this, disease specific survival is excellent.
Acknowledgments:
Daniel Scholfield was supported by The Dowager Countess Eleanor Peel Trust and The Colledge Family Memorial Fellowship Fund to undertake a Research Fellowship for 12 months.
Funding Statement:
Research reported in this publication was supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748.
Footnotes
Author Disclosure Statement: The authors have no conflicts of interest to disclose
Commercial and Financial Interests: The authors have no commercial or financial interests to disclose
References
- 1.Ganly I, Nixon IJ, Wang LY et al. Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It? Thyroid. (2015). doi: 10.1089/thy.2015.0104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. (2016). doi: 10.1089/thy.2015.0020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Vickery AL Jr, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M. Papillary carcinoma. Semin DiagnPathol. 1985;2(2):90–100. [PubMed] [Google Scholar]
- 4.Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. (2007). doi: 10.1007/s00268-006-0837-3 [DOI] [PubMed] [Google Scholar]
- 5.Baloch ZW, LiVolsi VA. Special types of thyroid carcinoma. Histopathology. (2018). doi: 10.1111/his.13348 [DOI] [PubMed] [Google Scholar]
- 6.Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review. Adv Ther. (2020). doi: 10.1007/s12325-020-01391-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Lloyd RV, Osamura RY, Klöppel G, et al. WHO Classification of Tumours of Endocrine Organs. Vol 10. Fourth Edition. Lyon, France: WHO/IARC Press, 2017. [Google Scholar]
- 8.Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006;72(5):438–44 [PubMed] [Google Scholar]
- 9.Pillai S, Gopalan V, Smith RA, Lam AK. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol (2015). doi: 10.1016/j.critrevonc.2014.12.001 [DOI] [PubMed] [Google Scholar]
- 10.Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. (2012). doi: 10.1245/s10434-011-2129-x [DOI] [PubMed] [Google Scholar]
- 11.Vuong HG, Kondo T, Pham TQ, et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. (2017). doi: 10.1530/EJE-16-0863 [DOI] [PubMed] [Google Scholar]
- 12.Malandrino P, Russo M, Regalbuto C, et al. Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. Thyroid. (2016) doi: 10.1089/thy.2016.0168 [DOI] [PubMed] [Google Scholar]
- 13.Regalbuto C, Malandrino P, Tumminia A, et al. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. (2011). doi: 10.1089/thy.2010.0331 [DOI] [PubMed] [Google Scholar]
- 14.Chereau N, Giudicelli X, Pattou F, et al. Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study. J Clin Endocrinol Metab. (2016). doi: 10.1210/jc.2016-2341 [DOI] [PubMed] [Google Scholar]
- 15.Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid (2008). doi: 10.1089/thy.2008.0164 [DOI] [PubMed] [Google Scholar]
- 16.Ganly I, Ibrahimpasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid. (2014). doi: 10.1089/thy.2013.0503 [DOI] [PubMed] [Google Scholar]
- 17.Russo M, Malandrino P, Moleti M, et al. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. J Endocrinol Invest. (2017). doi: 10.1007/s40618-017-0688-9 [DOI] [PubMed] [Google Scholar]
- 18.Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. EndocrPathol. (2022). doi: 10.1007/s12022-022-09707-3 [DOI] [PubMed] [Google Scholar]
- 19.Amin MB, Greene FL, Edge SB, et al. (eds). AJCC Cancer Staging Manual. 8th ed. Springer International Publishing: American Joint Commission on Cancer; New York, 2017. [Google Scholar]
- 20.Ho D, Imai K, King G, Stuart E. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011(42):28. [Google Scholar]
- 21.Kuo EJ, Goffredo P, Sosa JA, Roman S. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid. (2013). doi: 10.1089/thy.2012.0563 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Cavaco D, Martins AF, Cabrera R, Vilar H, Leite V. Diffuse sclerosing variant of papillary thyroid carcinoma: outcomes of 33 cases. Eur Thyroid J. (2022). doi: 10.1530/ETJ-21-0020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Saliba M, Alzumaili BA, Katabi N, et al. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients. Am J Surg Pathol. (2022). doi: 10.1097/PAS.0000000000001958 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg. (2009). doi: 10.1007/s00268-009-9940-6 [DOI] [PubMed] [Google Scholar]
- 25.Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid. (2009). doi: 10.1089/thy.2009.0073 [DOI] [PubMed] [Google Scholar]
- 26.Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. (2007). doi: 10.1038/modpathol.3800797 [DOI] [PubMed] [Google Scholar]
- 27.Joung JY, Kim TH, Jeong DJ, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Histopathology. (2016). doi: 10.1111/his.12902 [DOI] [PubMed] [Google Scholar]
- 28.Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma.Head Neck 2011;33:1052–1059; doi: 10.1002/hed.21494 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Figure S1: Histogram showing distribution of age at surgery in DS-PTC compared to cPTC and TC-PTC
Figure S2: Distribution of recurrence in DS-PTC (N = 39)
Figure S3: Standardized mean difference plot before and after matching for DS-PTC and cPTC
Figure S4: Standardized mean difference plot before and after matching for DS-PTC and TC-PTC
Figure S5: Unadjusted (pre-match) and adjusted (post-match) propensity score distribution graphs A) Age B) Sex C) T Stage D) N Stage E) M Stage. Blue = cPTC; Green = DS-PTC
Figure S6: Unadjusted (pre-match) and adjusted (post-match) propensity score distribution graphs A) Age B) Sex C) T Stage D) N Stage E) M Stage. Red = TC-PTC; Green = DS-PTC